Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sotevtamab Combined With Docetaxel in Metastatic NSCLC
NCT04364620Phase 2Completed
- Sponsor
- Alethia Biotherapeutics
- Start
- Feb 2021
- Primary completion
- Dec 2023
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of sotevtamab in non-small cell lung cancer (NSCLC), sponsored by Alethia Biotherapeutics. Started Feb 2021; status: completed.
02
Drugs
sotevtamab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04364620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04364620.